If a person's cell have the antigen, the antibody should NOT be present in that person's serum. If an antibody to a blood group antigen is present in the serum of a person, his or her cells should lack that antigen. The antigens are on the cells and the antibodies are in the serum.
Therapy-related myeloid leukemia (t-MDS/t-AML) is a well-recognized clinical syndrome occurring as a late complication following cytotoxic therapy.1â5 The term âtherapy-relatedâ leukemia is descriptive and based on a patientâs history of exposure to cytotoxic agents.
In AML, B7-H1 is a candidate molecule for inhibition of T cells. In a mouse model of AML, expression of B7-H1 allowed dormant tumor cells to escape from CTLs [4, 5, 6] [7, 8]. B7-H1 (also known as PD-L1 or CD274) is a B7 family member, and it is a ligand for PD-1 (programmed death-1, a member of the CD28 family) and B7.1 [9, 10, 11, 12].